Psychedelic Bulletin #138: Delix’s Non-Hallucinogenic Psychedelic Enters the Clinic; Arizona Earmarks $5m for Whole Mushroom Psilocybin Trials; MEPs form EU Action Group

The below updates are more granular than those in our Psychedelic Legalization & Decriminalization Tracker, which is produced with the support of experts at Calyx Law and Emerge Law Group.These updates reflect the period May 6th to 29th, 2023. SB 242 – NevadaRequires the Department of Health and Human Services to establish the Psychedelic Medicines Working GroupIntroduced: March 9, 2023Latest Action Date: May 29, 2023Latest Action: Passed by committeeNext Action: Advance for further floor action in the SenateOn May 29, 2023, the Committee on Finance recommended SB 242 pass as amended after being passed by the Committee on Health and Human Services in April. The bill will now advance for further floor action in the Senate, its house of origin. If enacted, the bill would require Nevada’s Department of Health and Human Services to “establish the Psychedelic Medicines Working Group to study certain issues relating to the therapeutic use of entheogens”. H 3605 – MassachusettsAn Act concerning the legal use of the plant medicine known as psilocybin for therapeutic, spiritual, and medicinal purposesIntroduced: March 30, 2023Latest Action Date: May 26, 2023Latest Action: Referred to Committee on Public HealthNext Action: Hearing scheduled for June 6, 2023On March 30, 2023, Massachusetts bill H 3605 was referred to the committee of Public Health. A hearing for the bill has since been scheduled for June 6, 2023. The bill, if passed, would see the Department of Public Health establish procedures “for the granting of psilocybin facilitator licences.” H 3574 – MassachusettsAn Act concerning the use of a prescription medicine that contains 3,4-methylenedioxymethamphetamine (MDMA)Introduced: March 3, 2023Latest Action Date: May 26, 2023Latest Action: Senate concurredNext Action: Hearing scheduled for June 6, 2023On March 30, 2023, bill H 3574 was introduced in Massachusetts. This bill, which seeks to establish a maximum treatment cost of $5,000 for MDMA-assisted therapy, was referred to the committees on Elder Affairs and Public Health. On May 26, 2023, a hearing was scheduled for the bill which is slated to take place on June 6, 2023. SB 806 – Rhode IslandAn Act Relating to Food and DrugsIntroduced: March 23, 2023Latest Action Date: May 26, 2023Latest Action: Hearing scheduled for June 1, 2023Next Action: Hearing to take placeOn March 23, 2023, SB 806 was introduced in Rhode Island and referred to the Senate Judiciary. On May 26, 2023 a hearing was scheduled for SB 806 which is to take place on June 1, 2023. This bill, if passed, would amend the “law on controlled substances  to permit a person to possess less than 1 ounce of psilocybin and would allow psilocybin to be cultivated at a person’s residence for personal use.” SB 303 – OregonRelating to psilocybin services; and prescribing an effective date.Introduced: January 9, 2023Latest Action Date: May 26, 2023Latest Action: Signed by Senate President and Speaker of the HouseNext Action: To be signed by Secretary of SenateOn May 23, 2023 Oregon’s SB 303 passed its third reading in the house. The bill, which has now passed both houses, has been signed by the Senate President and the Speaker of the House. SB 303 must now be signed by the Secretary of the Senate before it is sent to Oregon’s Governor where it can be signed into law. If passed into law, SB 303 would require psilocybin service centres and facilitators to collect and report data on client details, adverse events, and other related information. SB 58 – CaliforniaControlled substances: decriminalization of certain hallucinogenic substances.Introduced: December 16, 2022Latest Action Date: May 25, 2023Latest Action: In Assembly, First ReadingNext Action: Assembly voteOn May 24, 2023, California’s SB 58 was read for the third time. The bill was passed with 21 votes in favour and 16 votes in opposition. SB 58 was subsequently ordered to the Assembly where its first reading took place on May 25, 2023. The bill must now pass a vote in the Assembly before moving forward in the legislative process. If enacted, SB 58 would, amongst other things, “make lawful the possession, preparation, obtaining, transfer, as specified, or transportation of, specified quantities of psilocybin, psilocyn, dimethyltryptamine (DMT) , ibogaine, and mescaline, for personal use or facilitated or supported use, as defined, by and with persons 21 years of age or older.” SB 23-290 – ColoradoNatural Medicine Regulation And LegalizationIntroduced: April 18, 2023Latest Action Date: May 23, 2023Latest Action: Governor SignedOn May 2, 2023, Colorado’s Senate concurred with amendments made to SB 23-290 by the House. The bill was subsequently signed by the Speaker of the House and President of the Senate before being sent to Colorado’s Governor. On May 23, 2023 Governor Jared Polis signed SB 23-290 which clarifies and modifies parts of Colorado’s Natural Medicine Health Act which was passed in November 2022. LD 1914 – MaineAn Act To Enact The Maine Psilocybin Health Access ActIntroduced: May 9, 2023Latest Action Date: May 22, 2023Latest Action: Word session held, bill tabledOn May 9, 2023, LD 1914 was introduced in Maine. The bill, which seeks to “enact the Maine Psilocybin Health Access Act”, was then referred to the Committee on Veterans and Legal Affairs. Following a work session which was held on May 22, 2023, LD 1914 was delayed. HB 727 – North CarolinaBreakthrough Therapies Research/Advisory Act.Introduced: April 18, 2023Latest Action Date: May 16, 2023Latest Action: Referred to Committee on AppropriationsNext Action: Referral to Committee on Rules, Calendar, and Operations On April 18, 2023, HB 727 was introduced in North Carolina. After passing its first reading on April 19th, the bill was referred to the House Committee on Health. The bill was subsequently referred to the committee on Appropriations on May 16, 2023. If reported favourably, HB 727 will advance to the Committee on Rules, Calendar, and Operations before proceeding through the early steps in the legislative process. If eventually signed into law, HB 727 would establish a Breakthrough Therapies Research Grant Fund that would provide two $2.5m grants to North Carolina research projects investigating the use of MDMA or Psilocybin to treat certain psychiatric indications in qualifying patient populations. HB 6734 – ConnecticutAn act concerning the decriminalization of possession of small amounts of psilocybinIntroduced: February 22, 2023Latest Action Date: May 12, 2023Latest Action: Assigned Senate Calendar NumberNext Action: Senate voteOn May 10, 2023, after passing through the House, HB 6734 was tabled for the Calendar in the Senate. HB 6734 will now be debated and amendments to the bill can be proposed before a final Senate vote occurs. Should amendments be made, the bill will need to return to the first chamber for a subsequent vote. Should HB 6734 eventually be signed into law, criminal penalties for possession of up to one-half ounce of psilocybin would be eliminated. SB 5263 – WashingtonConcerning access to psilocybin services by individuals 21 years of age and older.Introduced: January 11, 2023Latest Action Date: May 9, 2023Latest Action: Partially vetoed and signed by GovernorOn April 20, 2023, Washington’s SB 5263 was delivered to the state’s governor after being accepted by both the House and Senate. SB 5263, when introduced, sought to regulate psilocybin services for individuals over the age of 21 in the state. However, SB 5263 underwent some significant changes after a Senate committee approved a substitute bill which narrowed the bill’s original scope in late February 2023. On May 9, 2023 Washington’s governor signed the substitute to SB 5263. However, the governor vetoed sections 1, 2, 3, 4, 5, 6, 10, and 11 of the bill. These sections would have seen the establishment of a psilocybin advisory board and an interagency working group between the aforementioned advisory board and the Department of Health, Department of Agriculture, and the Liquor and Cannabis Board. However, the governor stated that the “advisory board’s role is unclear” given that a similar task force, established last year, “has yet to complete its work.”



Source link